Cargando…
Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ
The protein kinase family includes attractive targets for drug development. Methods for screening of kinase inhibitors remain largely limited to in vitro catalytic assays. It has been shown that ATP-competitive inhibitors antagonize interaction between the target kinase and kinase-specific co-chaper...
Autores principales: | Sonamoto, Rie, Kii, Isao, Koike, Yuka, Sumida, Yuto, Kato-Sumida, Tomoe, Okuno, Yukiko, Hosoya, Takamitsu, Hagiwara, Masatoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522657/ https://www.ncbi.nlm.nih.gov/pubmed/26234946 http://dx.doi.org/10.1038/srep12728 |
Ejemplares similares
-
Reverse mutants of the catalytic 19 kDa mutant protein (nanoKAZ/nanoLuc) from Oplophorus luciferase with coelenterazine as preferred substrate
por: Inouye, Satoshi, et al.
Publicado: (2022) -
Selective inhibition of the kinase DYRK1A by targeting its folding process
por: Kii, Isao, et al.
Publicado: (2016) -
DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain
por: Abu Jhaisha, Samira, et al.
Publicado: (2017) -
An Alternative Method for Generating Arynes from ortho-Silylaryl Triflates: Activation by Cesium Carbonate in the Presence of a Crown Ether
por: Yoshida, Suguru, et al.
Publicado: (2015) -
Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy
por: Sako, Yukiya, et al.
Publicado: (2017)